Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

Thomas also held leadership posts with Novartis, Bristol-Myers Squibb ... In addition to developing WU-CART-007, a drug ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...

While Novartis provided an optimistic take on 2024, the lack of commentary on 2025 “may disappoint,” Bloomberg Intelligence ...